



IPW

PTO/SB/21 (02-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/779,724	
	Filing Date	02/18/2004	
	First Named Inventor	K.S. Keshava Murthy	
	Art Unit		
	Examiner Name		
Total Number of Pages in This Submission	104	Attorney Docket Number	PT2074001


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Margelo K. Sarkis, Registration No. 37,015
Signature	
Date	June 1, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT OFFICE

**CUSTOMER NO. 23607**

Application Serial No. 10/779,724

Our Ref.: PT2074001

Applicant: Apotex Pharmachem Inc.  
(formerly known as  
Brantford Chemicals Inc.)

Agent: Ivor M. Hughes,  
Suite 200,  
175 Commerce Valley  
Drive West,  
Thornhill, Ontario  
Canada L3T 7P6

Title: RESOLUTION OF RACEMATES OF METHYL  
ALPHA-5-[4,5,6,7-TETRAHYDRO[3,2-C]THIENOPYRIDYL]-(2-  
CHLOROPHENYL)ACETATE

Inventors: K.S. Keshava Murthy  
Elena Bejan  
Gamini Weeratunga

Filing Date: February 18, 2004

---

**INFORMATION DISCLOSURE STATEMENT**

June 1, 2004

The Commissioner of Patents  
UNITED STATES PATENT OFFICE  
2011 South Clark Place  
Crystal Plaza 2, Room 1B03  
Arlington, Virginia 22202  
U.S.A.

Dear Sir:

Applicants and the undersigned are aware of "patents, publications, or other information" which they believe may be material to the examination of the above-identified application. Copies of these items, and one sheet of Form PTO-1449 listing them, are submitted herewith pursuant to 37 C.F.R. §§ 1.97-1.99 and to the duty of disclosure set forth in 37. C.F.R. § 1.56. If a fee is required for the filing of

this information disclosure statement, please obtain such fee from Deposit Account 08-3255 and advise Applicant's Agent.

Although this Information Disclosure Statement identifies references which may be "material," it is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" (within the meaning of 35 U.S.C. §102 and §103) as to the invention disclosed and claimed in this application unless specifically designated as such. Moreover, no representation is intended as to the relative relevance of any portion of the references or as to the relevance among references, whether cited in this Statement or elsewhere.

In accordance with 37 C.F.R. §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a novelty search has been made or that no other information which may be material (as defined in 37 C.F.R. §1.56(a)) exists.

#### **UNITED STATES PATENT DOCUMENTS**

4,529,596  
4,847,265  
5,204,469  
5,225,420  
6,495,691  
2004/0024011  
2004/0024012

#### **FOREIGN PATENT DOCUMENTS**

None

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

"Clopidogrel Hydrogensulfate", Drugs of the Future, (1993), 18(2), p. 107-112

Respectfully submitted,

IVOR M. HUGHES

A handwritten signature in black ink, appearing to read "Marcelo Sarkis". The signature is fluid and cursive, with the first name "Marcelo" and last name "Sarkis" clearly distinguishable.

Marcelo K. Sarkis

Registration #37,015

Agent for Applicant

MKS\*kdK

Enclosures

## CITATION OF PRIOR ART

Sheet 1 of 1

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	PT. DOCKET NO. PT2074001	APPLICATION SERIAL NO. 10/779,724
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT K.S. Keshava Murthy et al.	
CUSTOMER NO. 23607		FILING DATE February 18, 2004	GROUP ART UNIT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,529,596	Jul-16-1985	Aubert et al.	514	231	
	4,847,265	Jul-11-1989	Badore et al.	514	301	
	5,204,469	Apr-20-1993	Descamps et al.	546	114	
	5,225,420	Jul-06-1993	Cazenave et al.	514	310	
	6,495,691	Dec-17-2002	Horne et al.	546	114	
	2004/0024011	Feb-05-2004	Valeriano et al.	514	301	
	2004/0024012	Feb-05-2004	Valeriano et al.	514	301	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	"Clopidogrel Hydrogensulfate", <u>Drugs of the Future</u> , (1993), 18(2), p. 107-112
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	